Paclitaxel-treated breast cancers display increased markers of TGF-β signaling, and TGF-β inhibition can enhance paclitaxel sensitivity against triple-negative breast cancer [106]. This evidence concerns the gene TGFB1 and triple-negative breast carcinoma.